Adlai Nortye enters clinical collaboration with Eli Lilly and Merck KGaA to evaluate AN4035 with cetuximab

Adlai Nortye ($ANL) has entered into a clinical collaboration with Eli Lilly and Merck KGaA to evaluate the combination of AN4035 and cetuximab. Cetuximab will be supplied by Lilly for U.S. trial sites and by Merck KGaA for the Australia and China trial sites.

Detected & updated continuously · Source: Nebula